Pulmonary Flashcards

1
Q

Asthma

A

A heterogeneous disease, usually characterized by chronic
airway inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Reps symptoms of asthma

A

wheeze
SOB
Chest tightness
cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Making the Diagnosis for asthma

A

Should be based on the history of characteristic symptom patterns
and evidence of airflow limitation.

  • Evidence of airflow limitation with bronchodilator reversibility

dults: Increase in FEV1 >12% and >200 mL from baseline, 10‒15 minutes after 200‒400 mcg albuterol or equivalent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

reliever meds to treat bronchospasm

A

SABA
inhaled corticosteroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
  • Controller To minimize development
    of airway inflammation
A

Example- Inhaled corticosteroid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Leukotriene modifier is used to

A

 To prevent inflammation development
* LTM such as montelukast
(Singulair®)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Long-acting muscarinic antagonists

A

To provide long-acting bronchodilation, potentially anti-eosinophilic/anti- inflammatory/controller effect

example: tiotropim bromide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Long-acting bronchodilators are used to

A

 To prevent development of
bronchospasm

Examples
 Long-acting beta2-agonist (LABA, salmeterol, formoterol)
 Long-acting muscarinic antagonists
(LAMA, tiotropium bromide)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Systemic corticosteroids

A

 To treat acute inflammation
* Example: Oral prednisone/prednisolone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

MOA of corticosteroids

A
  • Normally endogenously by adrenal cortex * Therapeutic use

 Inhibit production of inflammatory agents

  • Including cytokines, which reduces eosinophil infiltration, inhibits macrophage and eosinophil function
  • Decreases epithelium mediator cells, reduces vascular permeability, reduces the production of leukotrienes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA of Leukotriene modifiers

A

Selective and competitive antagonists of the cysteinyl leukotriene
(Cys LT1) receptor

 Cysteinyl leukotriene (LTC4, LTD4 and LTE4) production and receptor occupation, including airway edema, smooth muscle constriction, and altered cellular activity associated with inflammatory process

How well did you know this?
1
Not at all
2
3
4
5
Perfectly